(Q36213623)

12 August 2017

Physicochemical characterization of Remsima (English)

1 reference

12 August 2017

Soon Kwan Jung

1

1 reference

12 August 2017

Kyoung Hoon Lee

2

1 reference

12 August 2017

Jae Won Jeon

3

1 reference

12 August 2017

Joon Won Lee

4

1 reference

12 August 2017

Byoung Oh Kwon

5

1 reference

12 August 2017

Yeon Jung Kim

6

1 reference

12 August 2017

Jin Soo Bae

7

1 reference

12 August 2017

Dong-Il Kim

8

1 reference

12 August 2017

Soo Young Lee

9

1 reference

12 August 2017

Shin Jae Chang

10

1 reference

12 August 2017

1 January 2014

1 reference

12 August 2017

Monoclonal Antibodies

1 reference

12 August 2017

6

1 reference

12 August 2017

5

1 reference

12 August 2017

1163-1177

1 reference

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

Characterization of therapeutic antibodies and related products.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

The economic pressures for biosimilar drug use in cancer medicine

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

Comparability assessments of process and product changes made during development of two different monoclonal antibodies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

Version 1.2 of the Crystallography and NMR system

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

Coot: model-building tools for molecular graphics

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

Development of antibody arrays for monoclonal antibody Higher Order Structure analysis

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

A global comparability approach for biosimilar monoclonal antibodies using LC-tandem MS based proteomics

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622713

The FDA's assessment of follow-on protein products: a historical perspective

22 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25517302

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Processing of X-ray diffraction data collected in oscillation mode

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25517302

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/MABS.32221

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

25517302

1 reference